Back

Melanoma and Sarcoma Center - Clinical Trials

Specialty Cancer Centers

New Patient Appointment

321.841.8470

Clinical Trials

  • Phase 3 study for treatment of stage 3 Melanoma

    Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.

  • Phase 3 High Risk Resected Melanoma

    To compare overall survival (OS) of patients with resected Stage III and IV melanoma treated with high dose interferon alfa-2b versus MK-3475 (pembrolizumab)

  • Intermittent Vs Continuous Dosing of Dabrafenib and Trametinib

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

  • Phase 3 study for treatment of stage 3 Melanoma

    Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.

  • Phase 3 High Risk Resected Melanoma

    To compare overall survival (OS) of patients with resected Stage III and IV melanoma treated with high dose interferon alfa-2b versus MK-3475 (pembrolizumab)

  • Intermittent Vs Continuous Dosing of Dabrafenib and Trametinib

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

  • A Phase 1b/3, Multicenter Trial of Talimogene Laherparepvec

    Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intolerance of study treatment, up to a maximum of 24 months of study treatment. Subjects will be treated with MK-3475 (pembrolizumab) until complete response (CR) disease progression per irRC, or intolerance of study treatment, up to a maximum of 24 months of study treatment. In Phase 3, Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.

  • Intermittent Vs Continuous Dosing of Dabrafenib and Trametinib

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab

    •OS rate, defined as the proportion of patients alive after 2 years of follow-up time [ Time Frame: 2 years ] [ Designated as safety issue: No ] Will be estimated and compared between the two arms using the Fisher's exact test based on two-sided overall type I error rate of 0.05 adjusting for two-interim analysis. Distribution will be estimated using the Kaplan-Meier method.

  • A Randomized Phase II Trial of Intermittent Versus Continuous Dos

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.